研究人员宣布了一种常用减肥药利拉鲁肽(liraglutide)的临床试验的成功结果。对于超重或肥胖合并高心血管风险的成年人，每日一次利拉鲁肽(liraglutide)结合生活方式干预, 可显著降低与心脏健康风险相关的两类脂肪：内脏脂肪(visceral fat)和异位脂肪(ectopic fat)。这些结果显示利拉鲁肽治疗可显著降低该类人群患慢性病的风险。内脏脂肪(visceral fat)储存在腹腔内重要的内脏器官周围，如肝脏、胰腺和肠道。异位脂肪储存在通常含有少量脂肪的组织中，如肝脏、骨骼肌、心脏和胰腺(ectopic fat)。

Common weight-loss drug successfully targets fat that can endanger heart health

https://www.sciencedaily.com/releases/2021/08/210804123709.htm

Ian J Neeland, Steven P Marso, Colby R Ayers, Bienka Lewis, Robert Oslica, Wynona Francis, Susan Rodder, Ambarish Pandey, Parag H Joshi. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. The Lancet Diabetes & Endocrinology, 2021; DOI: 10.1016/S2213-8587(21)00179-0

---------------------

《肥胖的危害与科学减肥法》销售网址：

天猫（https://www.tmall.com/）、京东（https://www.jd.com/）等各大网店均有销售：

天猫：

https://list.tmall.com/search_product.htm?q=%B7%CA%C5%D6%B5%C4%CE%A3%BA%A6%D3%EB%BF%C6%D1%A7%BC%F5%B7%CA%B7%A8&type=p&spm=a220m.1000858.a2227oh.d100&from=.list.pc_1_searchbutton

京东：

https://search.jd.com/Search?keyword=%E8%82%A5%E8%83%96%E7%9A%84%E5%8D%B1%E5%AE%B3%E4%B8%8E%E7%A7%91%E5%AD%A6%E5%87%8F%E8%82%A5%E6%B3%95&enc=utf-8&pvid=b721ed307ebd40ec92864cfeee984141